Longboard Pharmaceuticals Inc LBPH

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%

24d ago, source: Yahoo Finance

Significantly high institutional ownership implies Longboard Pharmaceuticals ... for a business Every investor in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) should be aware of the most powerful ...

Longboard Pharmaceuticals Inc (LBPH) Shares Up Despite Recent Market Volatility

8d ago, source: newsheater

Longboard Pharmaceuticals Inc (NASDAQ: LBPH)’s stock price has soared by 11.69 in relation to previous closing price of 18.31. Nevertheless, the company has seen a gain of 10.60% in its stock price ...

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

3mon ago, source: Zacks.com on MSN

Longboard Pharmaceuticals, Inc. LBPH announced positive top-line results from the early to mid-stage PACIFIC study evaluating ...

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

1mon ago, source: Nasdaq

Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.

Longboard Pharmaceuticals Stock (NASDAQ:LBPH), Quotes and News Summary

3mon ago, source: Benzinga.com

Longboard Pharmaceuticals Inc (NASDAQ: LBPH) shares are trading lower by 11.3% to $22.26 Wednesday afternoon after the company announced that it commenced a $150 million underwritten public ...

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

17d ago, source: Business Wire

--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...

Bexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster Status

4d ago, source:

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on LBPH stock, giving a Buy rating yesterday. Patrick Trucchio ...

Longboard Pharmaceuticals Inc (LBPH)

3d ago, source: Investing

On Thursday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) received a Buy rating from Citi, with a set price target of $40. The coverage initiation follows a significant rally in the ...

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%

24d ago, source: Yahoo Finance

However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Longboard Pharmaceuticals, Inc.. It has a market capitalization of just US$715m, and ...

Longboard Pharmaceuticals Inc LBPH

29d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Longboard Pharmaceuticals Inc.

9mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...